Public-Private Partnerships: Compound and Data Sharing in Drug Discovery and Development

Davis, A. M.; Engkvist, Ola; Fairclough, Rebecca J.; Feierberg, Isabella; Freeman, Adrian; Iyer, Preeti

doi:10.1177/2472555220982268

Cited by 27 publications

(22 citation statements)

References 81 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Healthcare and pharmacy are areas where public-private partnerships have become quite widespread ( Davis et al, 2021 ). Thus, the experience of joint financing of the creation of digital pills, both by developer companies and government funds, should be noted ( Browne et al, 2018 ).…”

Section: Resultsmentioning

confidence: 99%

“…It has been established that the predominant type of financial resources used by researchers in the development of digital pills are proceeds from budget funds, and non-profit organizations. For example, it was revealed that in the field of digital pills, 14% (110) Healthcare and pharmacy are areas where public-private partnerships have become quite widespread (Davis et al, 2021). Thus, the experience of joint financing of the creation of digital pills, both by developer companies and government funds, should be noted (Browne et al, 2018).…”

Section: Figurementioning

confidence: 99%

See 1 more Smart Citation

Bibliometric analysis and evidence of clinical efficacy and safety of digital pills

et al. 2023

View full text Add to dashboard Cite

Objectives: Digital pills are new technologies that aim to improve healthcare by increasing medication adherence. The aim of the work was a bibliometric analysis of clinical studies of digital pills and an assessment of the level of evidence of their effectiveness, safety, and prospects for the future.Materials and Methods: The studies were conducted using online databases such as ClinicalTrials.gov, Dimensions, and Web of Science for the period January 2012 to July 2022. The VOSviewer tool for building and visualizing bibliometric networks was used.Results: Bibliometric analysis of the scientific literature revealed that over the past 10 years, the number of publications about digital pills has noticeably increased, which indicates the increasing importance of this field of knowledge. The leading positions in this area are occupied by scientists from the United States, the United Kingdom, and India. Sources of financial support for authors of publications in the field of digital pills are funds from leading developer companies, budget allocations, and funds from non-commercial organizations. Public-private partnerships are an important path to develop and implement digital pills. The four main clusters of digital pill studies were highlighted and visualized: efficacy and safety analysis for serious mental disorders; treatment and costs of tuberculosis therapy; features of the treatment of diabetes, cardiovascular diseases, and AIDS; and usage monitoring. Available publications demonstrate the efficacy potential and safety of digital pills. Nevertheless, the effects of digital pills have not yet been fully studied.Conclusion: Priority areas for future research are further randomized controlled clinical trials and meta-analyses, which are necessary for a high level (I level) of evidence for therapeutic applications of digital pills, as well as pharmacoeconomic studies.

show abstract

Section: Resultsmentioning

confidence: 99%

Section: Figurementioning

confidence: 99%

Bibliometric analysis and evidence of clinical efficacy and safety of digital pills

et al. 2023

View full text Add to dashboard Cite

show abstract

“…Non-EFPIA respondents were asked about their personal awareness of different assets whereas EFPIA respondents were asked about the awareness within their company. Asset awareness and sharing is a key success factor for PPPs ( 9 ). There are different models to achieve this.…”

Section: Discussionmentioning

confidence: 99%

Participating in innovative medicines initiative funded neurodegenerative disorder projects—An impact analysis conducted as part of the NEURONET project

et al. 2023

View full text Add to dashboard Cite

The European Commission's Innovative Medicines Initiative (IMI) has funded many projects focusing on neurodegenerative disorders (ND) that aimed to improve the diagnosis, prevention, treatment and understanding of NDs. To facilitate collaboration across this project portfolio, the IMI funded the “NEURONET” project between March 2019 and August 2022 with the aim of connecting these projects and promoting synergies, enhancing the visibility of their findings, understanding the impact of the IMI funding and identifying research gaps that warrant more/new funding. The IMI ND portfolio currently includes 20 projects consisting of 270 partner organizations across 25 countries. The NEURONET project conducted an impact analysis to assess the scientific and socio-economic impact of the IMI ND portfolio. This was to better understand the perceived areas of impact from those directly involved in the projects. The impact analysis was conducted in two stages: an initial stage developed the scope of the project, defined the impact indicators and measures to be used. A second stage designed and administered the survey amongst partners from European Federation of Pharmaceutical Industries and Associations (EFPIA) organizations and other partners (hereafter, referred to as “non-EFPIA” organizations). Responses were analyzed according to areas of impact: organizational, economic, capacity building, collaborations and networking, individual, scientific, policy, patient, societal and public health impact. Involvement in the IMI ND projects led to organizational impact, and increased networking, collaboration and partnerships. The key perceived disadvantage to project participation was the administrative burden. These results were true for both EFPIA and non-EFPIA respondents. The impact for individual, policy, patients and public health was less clear with people reporting both high and low impact. Overall, there was broad alignment between EFPIA and non-EFPIA participants' responses apart from for awareness of project assets, as part of scientific impact, which appeared to be slightly higher among non-EFPIA respondents. These results identified clear areas of impact and those that require improvement. Areas to focus on include promoting asset awareness, establishing the impact of the IMI ND projects on research and development, ensuring meaningful patient involvement in these public-private partnership projects and reducing the administrative burden associated with participation in them.

show abstract

“…Public-private partnerships (PPPs) is recognised worldwide as the key infrastructure delivery arrangement to finance, build and manage public facilities and services such as schools, railways, roads, houses and COVID-19 vaccines among others [1,2]. The arrangement, PPP, promotes and accepts the involvement of private investments into public sector management based on partnership agreements [3].…”

Section: Introductionmentioning

confidence: 99%

Criticality analysis of financial risks of public-private partnership projects in a Sub-Saharan African country

Akomea-Frimpong

Jin

Osei‐Kyei

2022

IOP Conf. Ser.: Earth Environ. Sci.

View full text Add to dashboard Cite

Integrating sustainable and complex financial performance models into Public-Private Partnership (PPP) project management is a challenging task due to the sheer number of inherent financial risks. Financial risk is a key impediment in the development of public infrastructure projects in Ghana. Studies on PPP projects in the country have concentrated on critical success factors and stakeholder management with little in-depth assessment of financial risks. This study develops and analyses the key financial risks of PPP infrastructure projects in Ghana. The research methodology is set as follows. First, the identification of twenty-eight financial risks in institutional and project reports, and peer-reviewed articles. Second, collection of primary data via surveys from 126 PPP experts (academics, risk managers and project managers). Third, the development and testing of a novel quantitative model on the criticality of financial risks of PPP projects. The findings show high interest charges, excessive operating expenses, and huge construction material costs as some of the critical financial risks that must be tackled immediately in the country. The outcomes of this study broaden the understanding of financial risks of PPP projects, and it sets the stage for further research.

show abstract

Public-Private Partnerships: Compound and Data Sharing in Drug Discovery and Development

Cited by 27 publications

References 81 publications

Bibliometric analysis and evidence of clinical efficacy and safety of digital pills

Bibliometric analysis and evidence of clinical efficacy and safety of digital pills

Participating in innovative medicines initiative funded neurodegenerative disorder projects—An impact analysis conducted as part of the NEURONET project

Criticality analysis of financial risks of public-private partnership projects in a Sub-Saharan African country

Contact Info

Product

Resources

About